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CASE REPORT Open Access
Plasma fibroblast skin tightening treatment
resulting in bilateral chemical eye injury
secondary to EMLA cream: a case report
Sirjhun Patel1,2* , Mohith Shamdas1,2 and Caroline Cobb1,2
Abstract
Background: Plasma fibroblast skin tightening treatment is a relatively novel and growing minimally invasive
aesthetic skin procedure. The treatment claims to rejuvenate skin by improving facial lines, wrinkles and skin
pigmentation associated with photo-ageing. The skin is often anaesthetised prior to the procedure with topical
creams such as EMLA (Eutectic mixture of local anaesthetics). We present the first case of bilateral chemical eye
injury following plasma fibroblast skin tightening treatment secondary to EMLA cream. EMLA cream was
inadvertently administered to both eyes in preparation for the treatment.
Case presentation: A patient was referred from the emergency department to a tertiary ophthalmology centre
with bilateral exquisite eye pain, inability to open the eyes, photosensitivity and reduced vision. She underwent
cosmetic plasma fibroblast skin tightening treatment at her local salon four hours earlier. She was found to have
bilateral alkali chemical eye injuries with significant diffuse corneal epithelial loss. The injury was thought to be
caused by inadvertent ocular exposure to EMLA cream, which was used in preparation for the plasma fibroblast
skin tightening treatment. She was treated with topical antibiotics and achieved satisfactory recovery.
Conclusion: This case report highlights a possible complication following plasma fibroblast skin tightening
treatment. We lay emphasis on the importance identifying chemical injury and recommend that medication
attention should be sought if there is any concern.
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Background
Demand for minimally-invasive aesthetic skin proce-
dures has spawned a number of treatment modalities for
skin regeneration and its rejuvenation. Touted as a tech-
nique for ‘non-surgical blepharoplasty’, plasma skin re-
generation is gaining popularity as a high-street aesthetic
procedure. This non-invasive procedure is especially
used in the treatment of mild upper dermatochalasis and
lower eyelid lines and wrinkles. It is also known as
‘fibroblast skin tightening’ or ‘plasma pen’. The exact
mechanism of its action is debated. An ultra-high-
frequency generator ionises inert atmospheric nitrogen
into an active plasma that delivers controlled thermal
energy to the skin via a handpiece [1]. The thermal en-
ergy is believed to remove old photodamaged epidermal
cells, and stimulate fibroblast activity and collagen
growth within the upper dermis [2]. Temporary hyper-
pigmentation is often reported in the immediate post-
procedural period, particularly with higher energy level
treatments [3]. The skin is commonly prepared with a
topical anaesthetic creams such as EMLA (Eutectic mix-
ture of local anaesthetics).
Lidocaine with prilocaine 5% cream is commonly
known by the trade name EMLA cream, which is an
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abbreviation for ‘eutectic mixture of local anaesthetics’.
Each gram of cream contains 25 mg lidocaine, 25 mg
prilocaine, macrogolglycerol hydroxystearate, carbopol
974P, sodium hydroxide and purified water [4]. It is
local anaethtic cream that is used commonly to an-
aesthetise the skin. Sodium hydroxide gives EMLA
cream an alkaline pH of 9, which allows for penetra-
tion of anaesthetic agents. It is currently available to
buy without a prescription from pharmacies in the
UK. Alkali agents are lipophilic and penetrate the eye
more rapidly than acids. Alkali chemicals penetrate
cell membranes through saponification and denature
the collagen matrix of the cornea [5]. The damaged
tissues can undertake liquefaction necrosis and se-
creted proteolytic enzymes which can lead to a cas-
cade of further damage.
EMLA cream is very well known to cause corneal
chemical alkaline burns from inadvertent exposure [6,
7]. Children have shown features of alkali eye injury
from EMLA cream after small amounts of the substance
has been self-applied accidently [8].
This case report describes the first case of bilateral
chemical eye injury caused form the plasma fibroblast
skin tightening procedure. EMLA cream was inadvert-
ently administered to both eyes in preparation for
treatment.
Case presentation
A 60 year old caucasian female underwent cosmetic
fibroblast skin tightening treatment around both her
eyelids at her local salon. She recalls some of the EMLA
cream (used as a topical anaesthetic) inadvertently seep-
ing into both her eyes during preparation for the treat-
ment. She experienced some initial discomfort, but
recalls it subsided and proceeded to have the fibroblast
treatment.
She presented approximately four hours later to the
emergency department with acute, bilateral, red, painful,
photophobic eyes with reduced vision and periorbital
swelling. She was referred as an emergency to ophthal-
mology with bilateral corneal injuries.
Her visual acuity on initial examination was 6/12 right
and 6/24 left. Examination was very difficult as she was
extremely photophobic and rated the pain as 10/10 on
the pain scale. pH was 7–8 in both eyes measured with
litmus paper.
On examination she was found to have bilateral diffuse
corneal epithelial loss affecting approximately 80% of
both corneas. These findings were consistent with a bi-
lateral corneal chemical alkaline injury. She also dis-
played marked periorbital oedema with multiple dot
burn lesions on her skin secondary to the plasma fibro-
blast treatment itself (Figs. 1 and 2).
The patient was treated with topical chloramphenicol
1% ointment every 2 h for both eyes, topical cyclopento-
late 1% and wore soft eye pads over her eyes overnight
for comfort. After day 1 of treatment, she was switched
to preservative free chloramphenicol 0.5% eye drops
4 times a day to both eyes and chloramphenicol oint-
ment once at night.
On day 5, the patient was prescribed preservative-free
sodium hyaluronate 0.2% lubricating eye drops for use
during the day and a paraffin-based ointment for use at
night.
Fig. 1 Bilateral periorbital oedema with multiple dot burn lesions on
her skin secondary to the plasma fibroblast skin
tightening treatment
Fig. 2 Bilateral periorbital oedema with multiple dot burn lesions on
her skin secondary to the plasma fibroblast skin
tightening treatment
Patel et al. BMC Ophthalmology          (2020) 20:342 Page 2 of 4
The patient had a visual acuity was 6/18 in both eyes
on review the following day. The patient was less photo-
phobic and fluorescein examination showed bilateral re-
solving epithelial defects. After day 1 of treatment the
right eye still had a large epithelial defect (Fig. 3). Fig-
ure 3 shows a large 4.3 mm by 6mm epithelial defect in
the right eye with 1% fluorescein illuminated with a co-
balt blue filter.
On day 5 follow up, the corneal epithelial defects
were mostly resolved with only a few diffuse punctate
epithelial erosions seen with fluorescein in both eyes.
The patient reported symptoms of dry eye and mild
photophobia. Visual acuity returned to 6/6 in both
eyes.
On day 25 of follow up the patient reported only
very mild dry eye symptoms and the ocular surface
had returned to normal in both eyes (Figs. 4 and 5).
The patient was advised that she is at risk of develop-
ing bilateral corneal recurrent erosion syndrome.
Discussion and conclusions
From this case we can infer that the patient sustained a
chemical eye injury secondary to inadvertent EMLA
cream instillation to the eyes in preparation for her
plasma fibroblast skin tightening treatment.
This case exhibits a delayed presentation of pain.
The patient felt an initial irritation from the EMLA
cream but this later subsided. She presented with
painful eyes approximately four hours after her treat-
ment at the salon. This is due to the anaesthetic ef-
fect of EMLA cream on the ocular surface. This
masking property of topical anaesthetics makes it
dangerous if not used appropriately. There is a case
report of a patient presenting with eye symptoms as
delayed as the following day after inadvertent expos-
ure to EMLA cream during skin treatment [9].
In this case, the pain settling proved to be inappro-
priately reassuring for both the patient and the practi-
tioner administering the skin treatment. Immediate
ocular surface irrigation was not commenced at the
salon. Rather, the occlusive effect of the patient clos-
ing her eyes may have resulted in retention of EMLA
cream over the ocular surface for the duration of the
treatment. We can assume that the chemical injury to
the ocular surface was intensified because of this. The
practitioner administering the local anaesthetic
claimed that she was unaware of the nature of EMLA
cream and that this information was not included in
her training. Considerable caution should be taken
when applying EMLA cream to the periocular skin as
there is a risk of migration of the anaesthetic to the
ocular surface. There is also a possibility of drug per-
meation through the skin of the eyelid which could
result in drug delivery to the conjunctiva and other
ocular tissues [10].
If EMLA cream comes into contact with the ocular
surface it is recommended to immediately irrigate the
eye with luke warm water or salt solution [4]. As topical
anaesthetics on the ocular surface can initially mask
symptoms – we recommend abandoning any skin
Fig. 3 Anterior segment view of the right eye illuminated with a
cobalt blue filter. Red arrow: A large 4.3 mm× 6mm corneal
epithelial defect visible with 1% fluorescein
Fig. 4 Pictures of the patients right and left ocular surface on day 25
of follow up
Fig. 5 Pictures of the patients right and left ocular surface on day 25
of follow up
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procedures until an appropriate assessment has been
made and sensation returns. If the eye is showing any
signs of irritation we recommend a low threshold to seek
advice from a trained medical clinician. Urgent attention
should be sought if there is any concern of chemical eye
injury. pH should be checked and copious irrigation
commenced without delay.
Abbreviation
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